- Trial Phase
- Phase 2
- Time to Market
- Unknown. The Phase 2 program is paused (Bio-Path owes over $355,000 to restart it), the company is seeking to sell its biotech IP, and no regulatory path is visible under the current plan.
- Why 3/10
- No hard, dated drug catalyst (PDUFA, pivotal readout, FDA advisory committee) is scheduled for prexigebersen in the next ~12 months: Phase 2 trials are paused for lack of funds, the company has signed non-binding LOIs to SELL its biotech IP, and it is pivoting to a crypto-treasury strategy — so the drug's next major event is a possible asset sale, not a clinical/regulatory binary, capping the impact score at 3.
Watch for (1) whether Bio-Path's non-binding LOIs to sell its biotech IP become definitive deals — that is now the only realistic value event for prexigebersen shareholders — and (2) the Series B Preferred authorization (each share convertible into 1,000 commons), which is a massive standing dilution overhang. Treat any prexigebersen "clinical progress" headline skeptically: the company disclosed it owes over $355,000 to MD Anderson just to restart its Phase 2 trials, and external web verification was unavailable this session (search provider down), so confidence in this read is lower than usual.
Price Chart
Executive Summary
Prexigebersen is Bio-Path Holdings' (BPTH, OTC, ~$0.035/share) lead Phase 2 oncology asset — but the company is effectively abandoning it: 2026 8-K analyses show a radical pivot from biotech to a crypto "Digital Asset Treasury 2.0" business, non-binding LOIs to sell the biotech IP, only ~$28,000 raised from recent Regulation A sales, and over $355,000 owed to MD Anderson just to restart the Phase 2 trials, plus a standing dilution overhang from 5 million Series B Preferred shares (each convertible into 1,000 common shares). The stock is down ~68% over 12 months with a strong bearish technical trend.
How It Works
Prexigebersen is Bio-Path's lead investigational cancer therapy, tested in Phase 2 in blood cancers. It has historically been described by the company as an antisense drug delivered in a liposome (a fat-bubble "delivery vehicle") — a synthetic piece of genetic material designed to block a protein that cancer cells need to grow.
Trial Status
Per Bio-Path's 2026 filings as analyzed locally: the Phase 2 trial program is stalled — the company disclosed it owes over $355,000 to MD Anderson to restart it — and it has signed non-binding letters of intent to sell its biotech IP while pivoting to a crypto "Digital Asset Treasury" strategy. Local FDA/ClinicalTrials.gov caches show no active Phase 2/3 prexigebersen trial records, FDA actions, or scheduled FDA catalysts for BPTH in the last year.
The Two-Sided Case
Upcoming Catalysts
- Outcome of the non-binding LOIs to sell Bio-Path's biotech IP (any definitive asset-sale agreement would be the main potential value event for prexigebersen).
- Execution of the crypto Digital Asset Treasury 2.0 pivot and any related equity issuances (Series B Preferred conversions / dilution).
- Any disclosure of funding to restart the paused Phase 2 trials at MD Anderson.
- Next quarterly earnings/10-Q filings (Q2 2026 earnings were scheduled 2026-08-12 per the local events calendar).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIO-PATH HOLDINGS, INC. 8-K BPTH ·Originating report